Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children

Novo Nordisk shares are up on Friday after reporting oral semaglutide trial results in children aged 10-17 years old with type 2 diabetes. Importance Rank: 1 read more

Go to News Site